AlphaCrest Capital Management LLC trimmed its position in uniQure (NASDAQ:QURE – Get Rating) by 26.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 50,412 shares of the biotechnology company’s stock after selling 18,490 shares during the quarter. AlphaCrest Capital Management LLC’s holdings in uniQure were worth $1,046,000 as of its most recent SEC filing.
Several other hedge funds have also recently modified their holdings of QURE. BlackRock Inc. raised its holdings in shares of uniQure by 241.0% in the 3rd quarter. BlackRock Inc. now owns 4,243,498 shares of the biotechnology company’s stock valued at $135,834,000 after purchasing an additional 2,998,944 shares during the period. Privium Fund Management UK Ltd bought a new position in uniQure in the 4th quarter valued at about $9,810,000. 683 Capital Management LLC raised its holdings in uniQure by 151.8% in the 3rd quarter. 683 Capital Management LLC now owns 711,355 shares of the biotechnology company’s stock valued at $22,771,000 after acquiring an additional 428,839 shares during the period. Principal Financial Group Inc. raised its holdings in uniQure by 2,374.6% in the 3rd quarter. Principal Financial Group Inc. now owns 254,112 shares of the biotechnology company’s stock valued at $8,134,000 after acquiring an additional 243,843 shares during the period. Finally, Morgan Stanley raised its holdings in uniQure by 180.7% in the 3rd quarter. Morgan Stanley now owns 296,829 shares of the biotechnology company’s stock valued at $9,502,000 after acquiring an additional 191,095 shares during the period. 81.35% of the stock is currently owned by institutional investors.
Several research analysts have weighed in on QURE shares. Stifel Nicolaus lowered their price target on shares of uniQure from $66.00 to $37.00 in a report on Thursday, May 5th. UBS Group upgraded shares of uniQure from a “neutral” rating to a “buy” rating and set a $40.00 target price on the stock in a research report on Thursday, March 17th. Chardan Capital decreased their target price on shares of uniQure from $95.00 to $65.00 in a research report on Wednesday, March 30th. Zacks Investment Research lowered shares of uniQure from a “hold” rating to a “sell” rating in a research report on Wednesday, May 4th. Finally, StockNews.com lowered shares of uniQure from a “hold” rating to a “sell” rating in a research report on Monday, May 9th. Two research analysts have rated the stock with a sell rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, uniQure presently has a consensus rating of “Buy” and an average target price of $50.45.
NASDAQ QURE opened at $14.31 on Friday. uniQure has a 1 year low of $12.52 and a 1 year high of $38.80. The company has a current ratio of 12.94, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $667.53 million, a price-to-earnings ratio of 2.08 and a beta of 1.13. The firm’s 50 day simple moving average is $16.73 and its 200 day simple moving average is $20.73.
uniQure (NASDAQ:QURE – Get Rating) last issued its earnings results on Monday, May 2nd. The biotechnology company reported ($1.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.07). uniQure had a net margin of 61.76% and a return on equity of 54.85%. On average, equities research analysts forecast that uniQure will post -3.54 earnings per share for the current year.
uniQure Company Profile (Get Rating)
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis.
- Get a free copy of the StockNews.com research report on uniQure (QURE)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.